Lifecycle Cost Analysis for Single-Use Systems - Less complicated single-use systems have more favorable lifecycle economics. - BioPharm International


Lifecycle Cost Analysis for Single-Use Systems
Less complicated single-use systems have more favorable lifecycle economics.

BioPharm International Supplements

Comparing Operating Costs

Table 3a. Rates used to estimate operating cost savings for single-use systems: Items for which costs are assumed to increase over time.
Comparing operating costs for stainless-steel and single-use systems is more complex as can be seen in Tables 3a, 3b, and 3c. Operating costs are calculated for the first 10 years of plant operation beginning in 2010. Operating costs such as water, personnel, and utilities should be escalated at a percentage rate that reflects local market economic conditions.

Table 3b. Rates and quantities used to estimate operating cost savings for single-use systems: Items which are assumed to be constant or which only affect the first year.
Plant capacity (number of fermentation batches) increases over the 10-year period, which is typical for many facilities. Plant capacity change over time is an important part of operating cost evaluation because capacity directly affects the cost of the single-use systems. Many operating costs for conventional stainless-steel systems also increase with increasing plant capacity (water, CIP chemicals) but some, such as the cost of routine maintenance, commissioning, validation, HVAC, and capital, do not.

Table 3c. Estimated operating cost savings for single-use systems
Moreover, the cost of WFI used in 2010 is five cents per liter. In much of the published literature, the cost of WFI is taken to be anywhere from 50 cents to one dollar per liter. Our experience is that these numbers overestimate the cost of WFI from a bulk generation and distribution system and unfairly slant many operating cost evaluations in favor of single-use systems. Five cents per liter is an all-in cost that includes the cost of capital, maintenance, validation, quality assurance, utilities, and waste-water discharge. It can be argued that the incremental cost of WFI is even lower because the facility is likely to have a bulk WFI generation and distribution system anyway to provide water for process as well as CIP of any remaining stainless-steel equipment. In this article, however, the price of WFI covers the total capital and operating costs of the bulk system.

Significant savings are projected in commissioning and qualification for this alternative, which is typical for single-use applications. We apply this as a one time savings in 2010 only. Experience is that ongoing validation costs for single-use and stainless-steel systems are similar.

The simple scenario described above, using single-use bags for buffer hold, realizes significant labor savings as a result of the way the single-use storage bags are used. For the stainless-steel case, each buffer was prepared for a single purification lot. In the single-use case, buffer is prepared in larger batches and aliquoted into single-use bags for multiple purification lots. This reduces the number of buffer preps required per week with corresponding savings in personnel, QA, CIP, and dispensing. We take credit for savings only when we have reduced operating hours sufficiently to eliminate a full time employee (FTE). The thinking is that saving only a few hundred hours doesn't reduce operating costs but merely lightens work schedules.

As Table 3c shows, operating cost savings for this scenario vary by year with a maximum savings of $383,000 in 2010 and a loss of $57,000 in 2013. The high savings in 2010 reflects the one time credit for savings in commissioning and qualification. For this alternative, savings increase as plant capacity increases, indicating the replacement cost of the single-use systems is less than the CIP and labor costs of the stainless-steel systems.

blog comments powered by Disqus



Bristol-Myers Squibb and Five Prime Therapeutics Collaborate on Development of Immunomodulator
November 26, 2014
Merck Enters into Licensing Agreement with NewLink for Investigational Ebola Vaccine
November 25, 2014
FDA Extends Review of Novartis' Investigational Compound for Multiple Myeloma
November 25, 2014
AstraZeneca Expands Biologics Manufacturing in Maryland
November 25, 2014
GSK Leads Big Pharma in Making Its Medicines Accessible
November 24, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here